Macquarie Group
DNLI icon

Macquarie Group’s Denali Therapeutics DNLI Stock Holding History

Macquarie Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-832
Closed -$72K – 1854
2022
Q3 		$72K Sell
832
-579
-41% -$18.8K ﹤0.01% 1848
2022
Q2 		$42K Hold
1,411
– – ﹤0.01% 2095
2022
Q1 		$45K Sell
1,411
-40,750
-97% -$1.4M ﹤0.01% 2169
2021
Q4 		$1.88M Buy
42,161
+251
+0.6% +$11.9K ﹤0.01% 1390
2021
Q3 		$2.11M Hold
41,910
– – ﹤0.01% 1371
2021
Q2 		$3.29M Sell
41,910
-1,022
-2% -$63.2K ﹤0.01% 1257
2021
Q1 		$2.45M Buy
42,932
+8,091
+23% +$542K ﹤0.01% 1131
2020
Q4 		$2.92M Buy
34,841
+31,030
+814% +$1.88M ﹤0.01% 998
2020
Q3 		$137K Hold
3,811
– – ﹤0.01% 1702
2020
Q2 		$92K Buy
+3,811
New +$89.6K ﹤0.01% 1775

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Macquarie Group's DNLI Position: Q4 2022 in Review

Macquarie Group sold out of Denali Therapeutics (DNLI) in Q4 2022, closing a stake of 832 shares — an estimated $72K sold.

Macquarie Group first reported a position in DNLI in Q2 2020 and held it in 10 quarters. The position peaked at $3.29M in Q2 2021. 197 funds tracked by Wall St. Rank hold DNLI as of Q4 2022.

  • Macquarie Group reported no remaining Denali Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Macquarie Group sold 832 Denali Therapeutics shares in Q4 2022, an estimated $72K.
  • Macquarie Group first reported a position in Denali Therapeutics in Q2 2020 and held it in 10 quarters.
  • Macquarie Group's Denali Therapeutics position peaked at $3.29M in Q2 2021.
  • 197 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.